Pioneering digital #biomarkers of neurological disease using augmented reality and machine learning.
Washington, DC
Joined May 2016
- Tweets1.5K
- Following239
- Followers482
- Likes298
Altoida, Inc. retweeted
New research in #DADM highlight @altoida NeuroMarker, a 10-minute self-administered digital cognitive assessment.
Findings support individuals identified as cognitively impaired were more likely to have elevated plasma pTau217🩸
alz-journals.onlinelibrary.w…
Altoida and @CircGenomics are combining Altoida's Digital NeuroMarker Platform with circRNA blood biomarkers: disease biology and cognitive function in one #Alzheimers pathway. Designed to run in primary care. First pilots later this year. prnewswire.com/news-releases…
@alzdemjournals #DADM: Dig cog assessment & BBM provide complementary insights into cognition and AD bio. Altoida identified MCI (AUC 0.89) increased the PPV of #pTau217 from 81.7% to 95.3% in model altoida.com/publications/ @IulitaMf @SantPauMemory @hospitalclinic @BarcelonaBeta
Read more: doi.org/10.1002/dad2.70486 Many thanks to other partners for their support @TheFlorey @QuanterixSimoa @JNJInnovMed
CEO Marc Jones joins the Next-Generation Neurology Diagnostics panel at Canaccord Genuity's Growth Conference, Aug 11–13 in Boston. Taking meetings all week. DM to connect. #CGDriven #DrivenByYourSuccess
Detecting cognitive impairment is rarely straightfwd. Early detection, differential diagnosis, & clinical implementation present unique challenges. At #AAIC26, 3 independent research teams will present studies evaluating Altoida's Digital NeuroMarker. #EarlyDetection #DigitalBio
Our CEO is at #BIO2026 this week and taking meetings. Biomarkers and therapies have moved fast. The functional measurement piece in between has more catching up to do. Contact us to schedule time. #BrainHealth #DigitalBiomarkers #Neurodegeneration
New episode of #AltoidaAtTheIntersection: Mike Zuendel on fighting for disease-modifying therapy, replacing "diagnosis" with "detection," and what patient-first measurement actually looks like when the disease doesn't wait 2 yrs between assessmts. Listen: youtu.be/_mL8uOsbLUI
June is #Alzheimer's & Brain Awareness Month. 8 in 10 adults over 65 say the word "dementia" carries stigma. When a word sounds like a verdict, people wait. That's what Mike Zuendel's Initiative to Change the "D-Word" is undoing.
notdemented.com #ENDALZ #ChangeTheDWord
"What's my Alzheimer's number?" Patient advocate Mike Zuendel asked it on Episode 2 of Altoida at the Intersection. Full episode out next week! #BrainHealth #Alzheimers #DigitalBiomarkers
The CEO of Altoida will join age-tech leaders at the American Society on Aging’s On Aging 2026 conference for the panel “How Age-Tech Innovators Are Transforming the Early Detection of Alzheimer’s,” discussing digital biomarkers, AI, and earlier cognitive detection #DigitalHealth
New GSA report: 95%+ of #primarycare physicians want to use digital cognitive assessments. Most are still relying on paper tests. Dr. Matt Anderson explores the adoption gap in Episode 1 of Altoida at the Intersection. youtu.be/s7YFw1rpV9Y #DigitalCognitiveAssessment
Healthcare has done this before. Diabetic retinopathy screening moved from specialty to primary care using digital tools + AI. Neurodegenerative care is next. Watch Altoida at the Intersection Ep1: youtu.be/s7YFw1rpV9Y #DigitalHealth #HealthSystems
Altoida will present new data on scaling early cognitive evaluation beyond specialty centers. As therapies and #bloodbiomarkers enter practice, detection must scale with them. Follow along for updates from Copenhagen. #DigitalHealth #AlzheimersResearch
New era in neurodegenerative care: therapies, #bloodbiomarkers & digital tools are here. Yet millions with #MCI remain undiagnosed. The bottleneck isn’t science. It’s system design. We’re launching #Altoida at the Intersection. Watch Episode 1: youtu.be/s7YFw1rpV9Y
What looks like a simple iPad assessment is a neuroscience-driven platform built on 20+ years of research. #Altoida’s Digital #NeuroMarker Platform captures motor, spatial & speech data to power scalable cognitive infrastructure. youtu.be/0yWka7_HkeE #DigitalHealth #MedTech
We’ll be presenting new data at #AAICNeuroNext on Altoida’s Digital NeuroMarker Platform for identifying MCI. Results show consistent performance across international cohorts, with alignment to established cognitive measures. Looking forward to the discussion.
Our CEO is in Dubai during the #WorldGovernmentSummit to engage with policymakers and global leaders on the future of health systems and technology-enabled care, particularly the role of scalable, validated digital tools in supporting earlier intervention + system sustainability.
We believe the future of brain health pairs digital functional assessment with targeted biology to support earlier understanding and more informed decisions at scale. That’s the direction Altoida is exploring with care models like @Mindspan. Read more: lnkd.in/g9VgjFYQ
We’re proud to co-host a mid-week conversation on what it takes to turn complex signals into real-world impact. If you’re investing in clinically grounded, scalable platforms, join us. Register here: form.jotform.com/25337448664…
Altoida will be in San Francisco for #JPM2026 week. We’re meeting with investors and strategic partners to discuss clinically validated #AI, #digitalbiomarkers and scalable platforms for the next phase of neurodegenerative care. Actively scheduling meetings. Let’s connect.
